Zhangjun Song
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhangjun Song has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Huxia Wang
Department of Breast Disease Center Shaanxi Provincial Tumor Hospital Xi'an Shaanxi China
3 shared publicationsBaoe Liu
Department of Breast Disease Center Shaanxi Provincial People's Hospital Xi'an 710068 Shaanxi China
1 shared publication- Bo Wang
Translational Medicine Center, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
1 shared publication Boyu Liang
Department of Surgical Oncology, Shaanxi Provincial People’s Hospital, Shaanxi, China
1 shared publication- Boyu Liang
Department of Ultrasound Medicine, Chinese First Affiliated Hospital of the People’s Liberation Army Air Force Medical University (Xijing Hospital), Xi’an, China
1 shared publication - Can Zhou
Department of Breast Surgery The First Affiliated Hospital of Xi'an Jiaotong University Xi'an China
1 shared publication
Latest Publications
- Open Access
- 20 March 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (12) , e48036
Development and validation of a multimodal ultrasound-mammography model for predicting axillary lymph node metastasis in clinical Tl breast cancer
With the global expansion of breast cancer screening, early-stage detection, particularly clinical stage T1 breast cancer, has become increasingly common. Accurate prognosis for T1 cancer is closely linked to lymph node metastasis status. While breast ultrasound and mammography are standard for screening, they are suboptimal for axillary lymph node assessment. This study aimed to predict lymph node metastasis by analyzing primary tumor imaging characteristics. We retrospectively analyzed 148 patients with pathologically confirmed stage T1 breast cancer. Multivariate logistic regression identified independent risk factors for lymph node metastasis from breast ultrasound and mammography features. Subsequently, a line graph model was established to predict axillary lymph node metastasis. A predictive nomogram was developed and validated, demonstrating good discrimination with area under the receiver operating characteristic curve of 0.78 (training set) and 0.72 (validation set). The model also showed favorable calibration and clinical utility via decision curve analysis. In conclusion, this model can provide risk stratification for clinical T1-stage breast cancer axillary lymph node metastasis, which to some extent aids clinical decision-making, thereby reducing missed diagnoses and unnecessary invasive procedures. However, further prospective validation is still required.
- 20 March 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (12) , e48036
Open AccessDevelopment and validation of a multimodal ultrasound-mammography model for predicting axillary lymph node metastasis in clinical Tl breast cancer
With the global expansion of breast cancer screening, early-stage detection, particularly clinical stage T1 breast cancer, has become increasingly common. Accurate prognosis for T1 cancer is closely linked to lymph node metastasis status. While breast ultrasound and mammography are standard for screening, they are suboptimal for axillary lymph node assessment. This study aimed to predict lymph node metastasis by analyzing primary tumor imaging characteristics. We retrospectively analyzed 148 patients with pathologically confirmed stage T1 breast cancer. Multivariate logistic regression identified independent risk factors for lymph node metastasis from breast ultrasound and mammography features. Subsequently, a line graph model was established to predict axillary lymph node metastasis. A predictive nomogram was developed and validated, demonstrating good discrimination with area under the receiver operating characteristic curve of 0.78 (training set) and 0.72 (validation set). The model also showed favorable calibration and clinical utility via decision curve analysis. In conclusion, this model can provide risk stratification for clinical T1-stage breast cancer axillary lymph node metastasis, which to some extent aids clinical decision-making, thereby reducing missed diagnoses and unnecessary invasive procedures. However, further prospective validation is still required.
- Open Access
- 9 September 2025
- Published by Springer Nature in Microchimica Acta
- Vol. 192 (10) , 1-16
Enhanced sensitivity detection via orientational labelling of SPA-functionalized magnetic nanoparticles in lateral-flow immunoassays
Mycoplasma pneumonia, a primary aetiological agent of atypical pneumonia, necessitates the implementation of rapid point-of-care diagnostics. Lateral flow immunoassays (LFIAs) hold promise for point-of-care testing (POCT), yet their sensitivity levels are frequently constrained by probe affinity and matrix interference. We introduce an orientational labelling strategy that employs magnetic nanoparticles (MNPs) functionalized with staphylococcal protein A (SPA) to simultaneously enhance antibody orientation and facilitate magnetic enrichment. The SPA–MNPs were synthesized via aggregation‒precipitation crosslinking, utilizing the Fc-binding specificity of SPA to enable oriented antibody conjugation and reduce steric hindrance. The oriented probe demonstrated robust stability, exceptional specificity, and enhanced binding affinity, which were considered crucial for the detection of low-abundance targets. In concentration gradient tests, the orientational labelling method resulted in the lowest visible colorimetric signals at 105 CFU·mL−1, whereas conventional random probes (BSA–MNPs) resulted in detectable coloration at concentrations as low as 106 CFU·mL−1. The color sensitivity and LOD of the orientational labelling approach were further increased to 104 CFU/mL and 0.668 × 104 CFU/mL, respectively, through magnetic enrichment treatment. The capture binding kinetics analysis indicated that the enrichment efficiency depended on the binding effect of the antibody and the antigen concentration, showing a clear correlation with the dissociation constant (KD). A clinical evaluation of 87 patient samples showed 88.5% agreement with the results of the quantitative fluorescence qPCR, which validated the diagnostic accuracy of the method. This study presents an orientational labelling platform for LFIA that combines Fc-directed antibody alignment with magnetic nanoparticle enrichment to overcome sensitivity barriers in the detection of low-abundance pathogens. This strategy comprises a universal design principle for achieving high-performance point-of-care testing (POCT) for various infectious diseases. Graphical Abstract
- 9 September 2025
- Published by Springer Nature in Microchimica Acta
- Vol. 192 (10) , 1-16
Open AccessEnhanced sensitivity detection via orientational labelling of SPA-functionalized magnetic nanoparticles in lateral-flow immunoassays
Mycoplasma pneumonia, a primary aetiological agent of atypical pneumonia, necessitates the implementation of rapid point-of-care diagnostics. Lateral flow immunoassays (LFIAs) hold promise for point-of-care testing (POCT), yet their sensitivity levels are frequently constrained by probe affinity and matrix interference. We introduce an orientational labelling strategy that employs magnetic nanoparticles (MNPs) functionalized with staphylococcal protein A (SPA) to simultaneously enhance antibody orientation and facilitate magnetic enrichment. The SPA–MNPs were synthesized via aggregation‒precipitation crosslinking, utilizing the Fc-binding specificity of SPA to enable oriented antibody conjugation and reduce steric hindrance. The oriented probe demonstrated robust stability, exceptional specificity, and enhanced binding affinity, which were considered crucial for the detection of low-abundance targets. In concentration gradient tests, the orientational labelling method resulted in the lowest visible colorimetric signals at 105 CFU·mL−1, whereas conventional random probes (BSA–MNPs) resulted in detectable coloration at concentrations as low as 106 CFU·mL−1. The color sensitivity and LOD of the orientational labelling approach were further increased to 104 CFU/mL and 0.668 × 104 CFU/mL, respectively, through magnetic enrichment treatment. The capture binding kinetics analysis indicated that the enrichment efficiency depended on the binding effect of the antibody and the antigen concentration, showing a clear correlation with the dissociation constant (KD). A clinical evaluation of 87 patient samples showed 88.5% agreement with the results of the quantitative fluorescence qPCR, which validated the diagnostic accuracy of the method. This study presents an orientational labelling platform for LFIA that combines Fc-directed antibody alignment with magnetic nanoparticle enrichment to overcome sensitivity barriers in the detection of low-abundance pathogens. This strategy comprises a universal design principle for achieving high-performance point-of-care testing (POCT) for various infectious diseases. Graphical Abstract
- Open Access
- 3 March 2025
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 16 (6) , 2026-2040
Identification of hub genes for the diagnosis and prognosis in triple negative breast cancer using transcriptome and differential methylation integration analysis
Introduction: Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. It is highly invasive and aggressive, making it the subtype of breast cancer with the poorest prognosis. Currently, systemic chemotherapy is the primary treatment option, but targeted therapies remain unavailable. Therefore, there is an urgent need to identify novel biomarkers for the early diagnosis and treatment of TNBC.
- 3 March 2025
- Published by Ivyspring International Publisher in Journal of Cancer
- Vol. 16 (6) , 2026-2040
Open AccessIdentification of hub genes for the diagnosis and prognosis in triple negative breast cancer using transcriptome and differential methylation integration analysis
Introduction: Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. It is highly invasive and aggressive, making it the subtype of breast cancer with the poorest prognosis. Currently, systemic chemotherapy is the primary treatment option, but targeted therapies remain unavailable. Therefore, there is an urgent need to identify novel biomarkers for the early diagnosis and treatment of TNBC.
- Open Access
- 22 March 2024
- Published by Impact Journals, LLC in Aging
- Vol. 16 (7) , 5967-5986
Identification and validation of DHCR7 as a diagnostic biomarker involved in the proliferation and mitochondrial function of breast cancer
Background: Energy metabolism has a complex intersection with pathogenesis and development of breast cancer (BC). This allows for the possibility of identifying energy-metabolism-related genes (EMRGs) as novel prognostic biomarkers for BC. 7-dehydrocholesterol reductase (DHCR7) is a key enzyme of cholesterol biosynthesis involved in many cancers, and in this paper, we investigate the effects of DHCR7 on the proliferation and mitochondrial function of BC. Methods: EMRGs were identified from the Gene Expression Omnibus (GEO) and MSigDB databases using bioinformatics methods. Key EMRGs of BC were then identified and validated by functional enrichment analysis, interaction analysis, weighted gene co-expression network analysis (WGCNA), least absolute shrinkage and selection operator (LASSO) regression, Cox analysis, and immune infiltration. Western blot, qRT-PCR, immunohistochemistry (IHC), MTT assay, colony formation assay and flow cytometry assay were then used to analyze DHCR7 expression and its biological effects on BC cells. Results: We identified 31 EMRGs in BC. These 31 EMRGs and related transcription factors (TFs), miRNAs, and drugs were enriched in glycerophospholipid metabolism, glycoprotein metabolic process, breast cancer, and cell cycle. Crucially, DHCR7 was a key EMRG in BC identified and validated by WGCNA, LASSO regression and receiver operating characteristic (ROC) curve analysis. High DHCR7 expression was significantly associated with tumor immune infiltration level, pathological M, and poor prognosis in BC. In addition, DHCR7 knockdown inhibited cell proliferation, induced apoptosis and affected mitochondrial function in BC cells. Conclusions: DHCR7 was found to be a key EMRG up-regulated in BC cells. This study is the first to our knowledge to report that DHCR7 acts as an oncogene in BC, which might become a novel therapeutic target for BC patients.
- 22 March 2024
- Published by Impact Journals, LLC in Aging
- Vol. 16 (7) , 5967-5986
Open AccessIdentification and validation of DHCR7 as a diagnostic biomarker involved in the proliferation and mitochondrial function of breast cancer
Background: Energy metabolism has a complex intersection with pathogenesis and development of breast cancer (BC). This allows for the possibility of identifying energy-metabolism-related genes (EMRGs) as novel prognostic biomarkers for BC. 7-dehydrocholesterol reductase (DHCR7) is a key enzyme of cholesterol biosynthesis involved in many cancers, and in this paper, we investigate the effects of DHCR7 on the proliferation and mitochondrial function of BC. Methods: EMRGs were identified from the Gene Expression Omnibus (GEO) and MSigDB databases using bioinformatics methods. Key EMRGs of BC were then identified and validated by functional enrichment analysis, interaction analysis, weighted gene co-expression network analysis (WGCNA), least absolute shrinkage and selection operator (LASSO) regression, Cox analysis, and immune infiltration. Western blot, qRT-PCR, immunohistochemistry (IHC), MTT assay, colony formation assay and flow cytometry assay were then used to analyze DHCR7 expression and its biological effects on BC cells. Results: We identified 31 EMRGs in BC. These 31 EMRGs and related transcription factors (TFs), miRNAs, and drugs were enriched in glycerophospholipid metabolism, glycoprotein metabolic process, breast cancer, and cell cycle. Crucially, DHCR7 was a key EMRG in BC identified and validated by WGCNA, LASSO regression and receiver operating characteristic (ROC) curve analysis. High DHCR7 expression was significantly associated with tumor immune infiltration level, pathological M, and poor prognosis in BC. In addition, DHCR7 knockdown inhibited cell proliferation, induced apoptosis and affected mitochondrial function in BC cells. Conclusions: DHCR7 was found to be a key EMRG up-regulated in BC cells. This study is the first to our knowledge to report that DHCR7 acts as an oncogene in BC, which might become a novel therapeutic target for BC patients.
- Open Access
- 25 August 2022
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 10 (16) , 884
Establishment and verification of a nomogram for predicting survival in patients with triple-positive breast cancer
Original Article Establishment and verification of a nomogram for predicting survival in patients with triple-positive breast cancer Xingguang Wang, Huxia Wang, Fende Liu, Lu Jie, Zhangjun Song
- 25 August 2022
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 10 (16) , 884
Open AccessEstablishment and verification of a nomogram for predicting survival in patients with triple-positive breast cancer
Original Article Establishment and verification of a nomogram for predicting survival in patients with triple-positive breast cancer Xingguang Wang, Huxia Wang, Fende Liu, Lu Jie, Zhangjun Song
- Open Access
- 16 August 2019
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-18
CRABP2 regulates invasion and metastasis of breast cancer through hippo pathway dependent on ER status
Triple Negative Breast cancer (TNBC) is incurable cancer with higher rates of relapse and shorter overall survival compared with other subtypes of breast cancer. Cellular retinoic acid binding protein 2 (CRABP2) belongs to fatty acid binding protein (FABP) family which binds with all-trans retinoic acid (RA). Previous studies from the database have reported the patients with high expression of CRABP2 showed different prognosis in ER+ and ER− breast cancer. However, its biological role and exact mechanism in breast cancer remain unknown. This aim of this study was to explore how CRABP2 regulated invasion and metastasis based on the estrogen receptor-α (herein called ER) status in breast cancer. Immunohistochemical staining method was used to analyze the expression of CRABP2 in human breast cancer tissues. Lentivirus vector-based shRNA technique was used to test the functional relevance of CRABP2 knockdown in breast tumors. Tail vein injection model was used to examine the lung metastasis. Co-immunoprecipitation, Western blotting, immunofluorescence, and quantitative reverse transcription polymerase chain reaction (RT-qPCR) were conducted to investigate the underlying mechanism that influenced the ER to the regulation of CRABP2 to Lats1. We observed that knockdown of CRABP2 promotes EMT, invasion and metastasis of ER+ breast cancer cells in vitro and in vivo, whereas overexpression of CRABP2 yields the reverse results. In ER+ mammary cancer cells, the interaction of CRABP2 and Lats1 suppress the ubiquitination of Lats1 to activate Hippo pathway to inhibit the invasion and metastasis of ER+ mammary cancer. However, in ER− mammary cancer cells, the interaction of CRABP2 and Lats1 promote the ubiquitination of Lats1 to inactivate Hippo pathway to promote the invasion and metastasis of ER− mammary cancer. Our findings indicate that CRABP2 can suppress invasion and metastasis of ER+ breast cancer and promote invasion and metastasis of ER− breast cancer by regulating the stability of Lats1 in vitro and in vivo, and it provides new ideas for breast cancer therapy.
- 16 August 2019
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 38 (1) , 1-18
Open AccessCRABP2 regulates invasion and metastasis of breast cancer through hippo pathway dependent on ER status
Triple Negative Breast cancer (TNBC) is incurable cancer with higher rates of relapse and shorter overall survival compared with other subtypes of breast cancer. Cellular retinoic acid binding protein 2 (CRABP2) belongs to fatty acid binding protein (FABP) family which binds with all-trans retinoic acid (RA). Previous studies from the database have reported the patients with high expression of CRABP2 showed different prognosis in ER+ and ER− breast cancer. However, its biological role and exact mechanism in breast cancer remain unknown. This aim of this study was to explore how CRABP2 regulated invasion and metastasis based on the estrogen receptor-α (herein called ER) status in breast cancer. Immunohistochemical staining method was used to analyze the expression of CRABP2 in human breast cancer tissues. Lentivirus vector-based shRNA technique was used to test the functional relevance of CRABP2 knockdown in breast tumors. Tail vein injection model was used to examine the lung metastasis. Co-immunoprecipitation, Western blotting, immunofluorescence, and quantitative reverse transcription polymerase chain reaction (RT-qPCR) were conducted to investigate the underlying mechanism that influenced the ER to the regulation of CRABP2 to Lats1. We observed that knockdown of CRABP2 promotes EMT, invasion and metastasis of ER+ breast cancer cells in vitro and in vivo, whereas overexpression of CRABP2 yields the reverse results. In ER+ mammary cancer cells, the interaction of CRABP2 and Lats1 suppress the ubiquitination of Lats1 to activate Hippo pathway to inhibit the invasion and metastasis of ER+ mammary cancer. However, in ER− mammary cancer cells, the interaction of CRABP2 and Lats1 promote the ubiquitination of Lats1 to inactivate Hippo pathway to promote the invasion and metastasis of ER− mammary cancer. Our findings indicate that CRABP2 can suppress invasion and metastasis of ER+ breast cancer and promote invasion and metastasis of ER− breast cancer by regulating the stability of Lats1 in vitro and in vivo, and it provides new ideas for breast cancer therapy.